A Phase 3 interventional study of Fingolimod in Relapsing Forms of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 458 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 2nd largest by enrollment, is one of 4 that started in 2010, is one of 12 in phase 3, and was the 12th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,125 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 2nd largest by enrollment of the 64 interventional ones that give a count, is one of 6 that started in 2010, is one of 23 in phase 3, and was the 16th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study combined all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that provided patients with continuous treatment until fingolimod was registered, commercially available, and reimbursed in the respective countries.
This study had two parts:
Key Inclusion Criteria:
Key Exclusion Criteria:
Any of the following cardiovascular conditions that have developed during the previous fingolimod study:
Any of the following pulmonary conditions during the previous fingolimod study:
The patient must have participated in a previous fingolimod trial to be eligible to participate in this trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label fingolimod 0.5 mg, taken orally once daily
Drug: Fingolimod
0.5 mg/day
Also known as: FTY720
Parts I and II: Number of Participants With Adverse Events, Serious Adverse Event, and Death
Analysis of absolute and relative frequencies for Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that Fingolimod 0.5 mg/day is safe in patients with relapsing forms of Multiple Sclerosis (MS) through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis performed.
Time frame: Baseline (Part I) to Month 6 Follow-up (Part II), up to 8 years
Part I: Aggregate Annualized Relapse Rates (ARR) From First Dose of Fingolimod
Annualized relapse rate (ARR) is defined as the number of all relapses (including both confirmed and unconfirmed relapses) experienced during a specific period of time adjusted to a one-year period. ARR is calculated as follows: (total number of all relapses) / (total number of days in the study for all patients for that specific period of time) x 365.25. Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.
Time frame: Month 0 (Core Baseline) to End of Follow-up Visit (an average of 162 months)
Part I: Number of Participants With Relapses (Confirmed and Unconfirmed) From First Dose of Fingolimod
A relapse is defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\<37.5°C) or infection. In Study Part One, a relapse must be confirmed by an Expanded Disability Status Scale (EDSS) certified Physician within 7 days of the onset of symptoms. A relapse is confirmed when it is accompanied by an increase of at least half a step (0.5) on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.
Time frame: Month 0 (Core Baseline) to End of Follow-up Visit (an average of 162 months)
Part I: Annualized Rates of New or Newly Enlarging T2 Lesions (ARneT2) Compared With First Dose of Fingolimod
Annualized rate of new/newly enlarging T2 lesions (ARneT2) is defined as the number of new or newly enlarging T2 lesions experienced during a specific period of time adjusted to a one-year period. ARneT2 was calculated as follows: (total number of new/newly enlarging T2 lesions) / (total number of days in the study for all patients for that specific period of time) x 365.25.Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.
Time frame: Month 0 (Core Baseline) to End of Study (an average of Month 156)
Part I: Change From First Dose of Fingolimod in Total T2 Lesions Volume
Total volume of T2 lesions was summarized by presenting descriptive statistics for change from first dose of fingolimod baseline values by visit.
Time frame: Month 3 to End of Study (Study Completion Visit)
Part I: Change From First Dose of Fingolimod in Total T1 Hypointense Lesions Volume
T1 hypointense lesion (black hole) volume was summarized by presenting descriptive statistics for change from first dose of fingolimod baseline values by visit.
Time frame: Month 3 to End of Study (Study Completion Visit)
Part I: Percent Brain Volume Change (PBVC) Relative to First Dose of Fingolimod
Descriptive statistics on percent brain volume change from first dose of fingolimod baseline were presented by visit. A negative change from baseline indicates improvement.
Time frame: Month 3 to Month 156
Part I: Annualized Rate of Brain Atrophy (ARBA) Relative to First Dose of Fingolimod
The annualized rate of brain volume change is an "averaged annual percentage change" in brain volume. ARBA was calculated as: ARBA = \[(SIENA/100+1) \^ (365.25/#days)-1\]\*100 where SIENA=(Vk/V0-1)\*100 and Vk is the brain volume at time k, V0 is the brain volume at time 0 and k is the total number of days in the study for all patients for that specific period of time) × 365.25. Only descriptive analysis performed.
Time frame: Month 3 to Month 156
Part I: Number of Participants With Confirmed 6-month Disability Progression After First Dose of Fingolimod
Disability progression was defined based on an increase in the EDSS score by 1.5 point for patients with a first dose of fingolimod (FDF) baseline EDSS score of 0, 1 point for patients with FDF baseline EDSS of \>=1 and \<=5.5, and by 0.5 points for patients with an FDF baseline EDSS\>5.5, confirmed after 6 months and all intermediate EDSS assessments. A 6-month confirmed disability progression was defined as a 6-month sustained increase from the reference (potential onset of progression) value in the EDSS scores. i.e., every EDSS score (scheduled or unscheduled) within a 6-month duration after the first progression should meet the progression criteria as specified above. The confirmation could only happen at a scheduled visit and in the absence of a relapse. Only descriptive analysis performed.
Time frame: Month 12 to Month 156
Part I: Number of Participants With Categorized Change From First Dose of Fingolimod in Expanded Disability Status Scale (EDSS) Overall Score
The EDSS is a scale for assessing neurological impairment in MS (Kurtzke 1983) including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's overall score is categorized as Improvement, Stable or Deterioration. If baseline EDSS score is \<=5, improvement is indicated by an EDSS score change of \<= -1, stable is indicated by an EDSS score change of \> -1 and \<= 0.5, deterioration is indicated by an EDSS score change of \> 0.5; if baseline EDSS score is \> 5, improvement is indicated by an EDSS score change of \<= -0.5, stable is indicated by an EDSS score change of \> -0.5 and \<= 0, deterioration is indicated by an EDSS score change of \> 0. Only descriptive analysis performed.
Time frame: Month 3 to Month 6 Follow-up
Part I: Change From First Dose of Fingolimod in Expanded Disability Status Scale (EDSS)
The EDSS is a scale for assessing neurological impairment in MS (Kurtzke 1983) including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's overall score is determined between 0 to 10. A negative change from baseline indicates improvement. Only descriptive analysis performed.
Time frame: Month 0 (Core Baseline) to End of Follow-up Visit (an average of 162 months)
This was an open-label, multi-center, single treatment arm design allowing patients participating in the fingolimod MS clinical development program to enroll in order to collect additional long-term safety, tolerability, efficacy, and health outcomes data.
| Milestone | Fingolimod 0.5 mg/Day |
|---|---|
| Started | 4125 |
| Safety set | 4083 |
| Fingolimod full analysis set | 4046 |
| Completed | 3481 |
| Not completed | 644 |
| Withdrew: Adverse event | 170 |
| Withdrew: Abnormal laboratory value(s) | 51 |
| Withdrew: Abnormal test procedure result(s) | 3 |
| Withdrew: Unsatisfactory therapeutic effect | 112 |
| Withdrew: Condition no longer requires study drug | 12 |
| Withdrew: Withdrawal by subject | 144 |
| Withdrew: Lost to follow-up | 50 |
| Withdrew: Administrative problems | 74 |
| Withdrew: Death | 16 |
| Withdrew: Protocol violation | 12 |
Analysis of absolute and relative frequencies for Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that Fingolimod 0.5 mg/day is safe in patients with relapsing forms of Multiple Sclerosis (MS) through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis performed.
| Participants | Fingolimod 0.5 mg/Day |
|---|---|
| Adverse Event (AEs) | 2125 |
| Serious Adverse Events (SAEs) | 515 |
| Deaths | 16 |
Annualized relapse rate (ARR) is defined as the number of all relapses (including both confirmed and unconfirmed relapses) experienced during a specific period of time adjusted to a one-year period. ARR is calculated as follows: (total number of all relapses) / (total number of days in the study for all patients for that specific period of time) x 365.25. Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.
| Annual number of relapses per patient | Fingolimod 0.5 mg/Day |
|---|---|
| Month 0 to Month 6 | 0.325 |
| Month 0 to Month 12 | 0.273 |
| Month 0 to Month 24 | 0.237 |
| Month 0 to Month 36 | 0.217 |
| Month 0 to Month 48 | 0.208 |
| Month 0 to Month 60 | 0.197 |
| Month 0 to Month 72 | 0.190 |
| Month 0 to Month 84 | 0.182 |
| Month 0 to Month 96 | 0.177 |
| Month 0 to Month 108 | 0.172 |
| Month 0 to Month 120 | 0.170 |
| Month 0 to Month 132 | 0.170 |
| Month 0 to Month 144 | 0.169 |
| Month 0 to Month 156 | 0.169 |
| Month 0 to end of Study | 0.166 |
| Month 0 to end of Follow-up | 0.169 |
A relapse is defined as the appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\<37.5°C) or infection. In Study Part One, a relapse must be confirmed by an Expanded Disability Status Scale (EDSS) certified Physician within 7 days of the onset of symptoms. A relapse is confirmed when it is accompanied by an increase of at least half a step (0.5) on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.
| Participants | Fingolimod 0.5 mg/Day |
|---|---|
| Month 0 to Month 6 | 655 |
| Month 0 to Month 12 | 992 |
| Month 0 to Month 24 | 1461 |
| Month 0 to Month 36 | 1794 |
| Month 0 to Month 48 | 2127 |
| Month 0 to Month 60 | 2383 |
| Month 0 to Month 72 | 2616 |
| Month 0 to Month 84 | 2793 |
| Month 0 to Month 96 | 2944 |
| Month 0 to Month 108 | 3036 |
| Month 0 to Month 120 | 3063 |
| Month 0 to Month 132 | 3072 |
| Month 0 to Month 144 | 3075 |
| Month 0 to Month 156 | 3079 |
| Month 0 to end of Study | 2970 |
| Month 0 to end of Follow-up | 3079 |
Annualized rate of new/newly enlarging T2 lesions (ARneT2) is defined as the number of new or newly enlarging T2 lesions experienced during a specific period of time adjusted to a one-year period. ARneT2 was calculated as follows: (total number of new/newly enlarging T2 lesions) / (total number of days in the study for all patients for that specific period of time) x 365.25.Month 0 is the first dose of fingolimod study drug among all studies in which patient participated. Only descriptive analysis performed.
| Annual number of T2 lesions per patient | Fingolimod 0.5 mg/Day |
|---|---|
| Month 0 to Month 3 | 12.324 |
| Month 0 to Month 6 | 2.073 |
| Month 0 to Month 12 | 1.360 |
| Month 0 to Month 24 | 1.042 |
| Month 0 to Month 36 | 1.011 |
| Month 0 to Month 48 | 1.008 |
| Month 0 to Month 60 | 0.957 |
| Month 0 to Month 72 | 0.963 |
| Month 0 to Month 84 | 0.906 |
| Month 0 to Month 96 | 0.813 |
| Month 0 to Month 108 | 0.713 |
| Month 0 to Month 120 | 0.702 |
| Month 0 to Month 132 | 0.659 |
| Month 0 to Month 144 | 0.681 |
| Month 0 to Month 156 | 0.637 |
| Month 0 to end of study | 0.751 |
Total volume of T2 lesions was summarized by presenting descriptive statistics for change from first dose of fingolimod baseline values by visit.
| mm^3 | Fingolimod 0.5 mg/Day |
|---|---|
| T2 volume change at Month 3 | -749.5 ± 5269.04 |
| T2 volume change at Month 6 | -207.0 ± 1385.64 |
| T2 volume change at Month 12 | -55.0 ± 1700.16 |
| T2 volume change at Month 24 | 16.2 ± 2009.87 |
| T2 volume change at Month 36 | 235.8 ± 2519.39 |
| T2 volume change at Month 48 | 875.1 ± 4145.99 |
| T2 volume change at Month 60 | 1546.3 ± 4556.51 |
| T2 volume change at Month 72 | 1719.2 ± 5184.27 |
| T2 volume change at Month 84 | 1635.8 ± 5075.13 |
| T2 volume change at Month 96 | 1303.9 ± 4712.78 |
| T2 volume change at Month 108 | 1562.0 ± 4654.67 |
| T2 volume change at Month 120 | 1393.1 ± 4908.76 |
| T2 volume change at Month 132 | 905.9 ± 3960.94 |
| T2 volume change at Month 144 | 702.7 ± 3765.80 |
| T2 volume change at Month 156 | 274.0 ± 5784.85 |
| T2 volume change at End of Study | 1588.5 ± 5157.00 |
T1 hypointense lesion (black hole) volume was summarized by presenting descriptive statistics for change from first dose of fingolimod baseline values by visit.
| mm^3 | Fingolimod 0.5 mg/Day |
|---|---|
| T1 volume change at Month 3 | -519.8 ± 1339.62 |
| T1 volume change at Month 12 | 49.1 ± 718.77 |
| T1 volume change at Month 24 | 64.1 ± 786.02 |
| T1 volume change at Month 36 | 151.08 ± 1001.28 |
| T1 volume change at Month 48 | 524.8 ± 1706.26 |
| T1 volume change at Month 60 | 853.6 ± 1957.74 |
| T1 volume change at Month 72 | 975.7 ± 2637.67 |
| T1 volume change at Month 84 | 930.1 ± 2471.70 |
| T1 volume change at Month 96 | 753.4 ± 1845.63 |
| T1 volume change at Month 108 | 628.7 ± 1922.45 |
| T1 volume change at Month 120 | 817.3 ± 2198.58 |
| T1 volume change at Month 132 | 726.7 ± NA |
| T1 volume change at End of Study | 800.6 ± 2247.27 |
Descriptive statistics on percent brain volume change from first dose of fingolimod baseline were presented by visit. A negative change from baseline indicates improvement.
| Percent change | Fingolimod 0.5 mg/Day |
|---|---|
| Percent volume change at Month 3 | -0.19 ± 0.660 |
| Percent volume change at Month 6 | -0.20 ± 0.801 |
| Percent volume change at Month 12 | -0.36 ± 0.901 |
| Percent volume change at Month 24 | -0.74 ± 1.209 |
| Percent volume change at Month 36 | -1.03 ± 1.541 |
| Percent volume change at Month 48 | -1.44 ± 1.851 |
| Percent volume change at Month 60 | -1.65 ± 2.196 |
| Percent volume change at Month 72 | -2.02 ± 2.514 |
| Percent volume change at Month 84 | -2.38 ± 2.638 |
| Percent volume change at Month 96 | -2.41 ± 2.607 |
| Percent volume change at Month 108 | -2.91 ± 2.863 |
| Percent volume change at Month 120 | -3.42 ± 2.911 |
| Percent volume change at Month 132 | -4.61 ± 2.511 |
| Percent volume change at Month 144 | -4.21 ± 2.778 |
| Percent volume change at Month 156 | -4.33 ± 3.146 |
The annualized rate of brain volume change is an "averaged annual percentage change" in brain volume. ARBA was calculated as: ARBA = \[(SIENA/100+1) \^ (365.25/#days)-1\]\*100 where SIENA=(Vk/V0-1)\*100 and Vk is the brain volume at time k, V0 is the brain volume at time 0 and k is the total number of days in the study for all patients for that specific period of time) × 365.25. Only descriptive analysis performed.
| Ratio | Fingolimod 0.5 mg/Day |
|---|---|
| Month 3 | -0.73 ± 2.834 |
| Month 6 | -0.39 ± 1.590 |
| Month 12 | -0.35 ± 0.891 |
| Month 24 | -0.37 ± 0.615 |
| Month 36 | -0.35 ± 0.522 |
| Month 48 | -0.37 ± 0.480 |
| Month 60 | -0.34 ± 0.451 |
| Month 72 | -0.35 ± 0.433 |
| Month 84 | -0.35 ± 0.395 |
| Month 96 | -0.31 ± 0.340 |
| Month 108 | -0.33 ± 0.326 |
| Month 120 | -0.36 ± 0.308 |
| Month 132 | -0.43 ± 0.240 |
| Month 144 | -0.36 ± 0.244 |
| Month 156 | -0.35 ± 0.256 |
Disability progression was defined based on an increase in the EDSS score by 1.5 point for patients with a first dose of fingolimod (FDF) baseline EDSS score of 0, 1 point for patients with FDF baseline EDSS of \>=1 and \<=5.5, and by 0.5 points for patients with an FDF baseline EDSS\>5.5, confirmed after 6 months and all intermediate EDSS assessments. A 6-month confirmed disability progression was defined as a 6-month sustained increase from the reference (potential onset of progression) value in the EDSS scores. i.e., every EDSS score (scheduled or unscheduled) within a 6-month duration after the first progression should meet the progression criteria as specified above. The confirmation could only happen at a scheduled visit and in the absence of a relapse. Only descriptive analysis performed.
| Participants | Fingolimod 0.5 mg/Day |
|---|---|
| Month 12 | 212 |
| Month 24 | 336 |
| Month 36 | 434 |
| Month 48 | 519 |
| Month 60 | 590 |
| Month 72 | 659 |
| Month 84 | 714 |
| Month 96 | 753 |
| Month 108 | 767 |
| Month 120 | 772 |
| Month 132 | 775 |
| Month 144 | 776 |
| Month 156 | 777 |
The EDSS is a scale for assessing neurological impairment in MS (Kurtzke 1983) including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's overall score is categorized as Improvement, Stable or Deterioration. If baseline EDSS score is \<=5, improvement is indicated by an EDSS score change of \<= -1, stable is indicated by an EDSS score change of \> -1 and \<= 0.5, deterioration is indicated by an EDSS score change of \> 0.5; if baseline EDSS score is \> 5, improvement is indicated by an EDSS score change of \<= -0.5, stable is indicated by an EDSS score change of \> -0.5 and \<= 0, deterioration is indicated by an EDSS score change of \> 0. Only descriptive analysis performed.
| Participants | Fingolimod 0.5 mg/Day |
|---|---|
| Month 3 — Improvement | 374 |
| Month 3 — Stable | 3126 |
| Month 3 — Deterioration | 269 |
| Month 6 — Improvement | 508 |
| Month 6 — Stable | 2900 |
| Month 6 — Deterioration | 340 |
| Month 9 — Improvement | 482 |
| Month 9 — Stable | 2425 |
| Month 9 — Deterioration | 304 |
| Month 12 — Improvement | 422 |
| Month 12 — Stable | 1930 |
| Month 12 — Deterioration | 322 |
| Month 15 — Improvement | 405 |
| Month 15 — Stable | 1764 |
| Month 15 — Deterioration | 285 |
| Month 18 — Improvement | 345 |
| Month 18 — Stable | 1361 |
| Month 18 — Deterioration | 271 |
| Month 21 — Improvement | 376 |
| Month 21 — Stable | 1524 |
| Month 21 — Deterioration | 287 |
| Month 24 — Improvement | 320 |
| Month 24 — Stable | 1299 |
| Month 24 — Deterioration | 294 |
| Month 27 — Improvement | 313 |
| Month 27 — Stable | 1271 |
| Month 27 — Deterioration | 270 |
| Month 30 — Improvement | 305 |
| Month 30 — Stable | 1204 |
| Month 30 — Deterioration | 287 |
| Month 33 — Improvement | 326 |
| Month 33 — Stable | 1172 |
| Month 33 — Deterioration | 292 |
| Month 36 — Improvement | 309 |
| Month 36 — Stable | 1065 |
| Month 36 — Deterioration | 288 |
| Month 39 — Improvement | 284 |
| Month 39 — Stable | 1015 |
| Month 39 — Deterioration | 276 |
| Month 42 — Improvement | 282 |
| Month 42 — Stable | 948 |
| Month 42 — Deterioration | 287 |
| Month 45 — Improvement | 244 |
| Month 45 — Stable | 875 |
| Month 45 — Deterioration | 263 |
| Month 48 — Improvement | 250 |
| Month 48 — Stable | 838 |
| Month 48 — Deterioration | 264 |
| Month 51 — Improvement | 244 |
| Month 51 — Stable | 784 |
| Month 51 — Deterioration | 247 |
| Month 54 — Improvement | 256 |
| Month 54 — Stable | 788 |
| Month 54 — Deterioration | 251 |
| Month 57 — Improvement | 201 |
| Month 57 — Stable | 694 |
| Month 57 — Deterioration | 245 |
| Month 60 — Improvement | 175 |
| Month 60 — Stable | 577 |
| Month 60 — Deterioration | 234 |
| Month 63 — Improvement | 182 |
| Month 63 — Stable | 540 |
| Month 63 — Deterioration | 191 |
| Month 66 — Improvement | 165 |
| Month 66 — Stable | 499 |
| Month 66 — Deterioration | 216 |
| Month 69 — Improvement | 156 |
| Month 69 — Stable | 503 |
| Month 69 — Deterioration | 193 |
| Month 72 — Improvement | 143 |
| Month 72 — Stable | 440 |
| Month 72 — Deterioration | 206 |
| Month 75 — Improvement | 156 |
| Month 75 — Stable | 437 |
| Month 75 — Deterioration | 201 |
| Month 78 — Improvement | 136 |
| Month 78 — Stable | 398 |
| Month 78 — Deterioration | 226 |
| Month 81 — Improvement | 150 |
| Month 81 — Stable | 456 |
| Month 81 — Deterioration | 217 |
| Month 84 — Improvement | 132 |
| Month 84 — Stable | 407 |
| Month 84 — Deterioration | 207 |
| Month 87 — Improvement | 147 |
| Month 87 — Stable | 450 |
| Month 87 — Deterioration | 227 |
| Month 90 — Improvement | 120 |
| Month 90 — Stable | 413 |
| Month 90 — Deterioration | 204 |
| Month 93 — Improvement | 143 |
| Month 93 — Stable | 386 |
| Month 93 — Deterioration | 187 |
| Month 96 — Improvement | 117 |
| Month 96 — Stable | 375 |
| Month 96 — Deterioration | 186 |
| Month 99 — Improvement | 110 |
| Month 99 — Stable | 325 |
| Month 99 — Deterioration | 159 |
| Month 102 — Improvement | 94 |
| Month 102 — Stable | 283 |
| Month 102 — Deterioration | 154 |
| Month 105 — Improvement | 103 |
| Month 105 — Stable | 261 |
| Month 105 — Deterioration | 131 |
| Month 108 — Improvement | 87 |
| Month 108 — Stable | 287 |
| Month 108 — Deterioration | 138 |
| Month 111 — Improvement | 74 |
| Month 111 — Stable | 198 |
| Month 111 — Deterioration | 101 |
| Month 114 — Improvement | 45 |
| Month 114 — Stable | 181 |
| Month 114 — Deterioration | 79 |
| Month 117 — Improvement | 31 |
| Month 117 — Stable | 94 |
| Month 117 — Deterioration | 52 |
| Month 120 — Improvement | 19 |
| Month 120 — Stable | 88 |
| Month 120 — Deterioration | 42 |
| Month 123 — Improvement | 9 |
| Month 123 — Stable | 36 |
| Month 123 — Deterioration | 21 |
| Month 126 — Improvement | 14 |
| Month 126 — Stable | 45 |
| Month 126 — Deterioration | 26 |
| Month 129 — Improvement | 6 |
| Month 129 — Stable | 18 |
| Month 129 — Deterioration | 12 |
| Month 132 — Improvement | 11 |
| Month 132 — Stable | 36 |
| Month 132 — Deterioration | 21 |
| Month 135 — Improvement | 5 |
| Month 135 — Stable | 19 |
| Month 135 — Deterioration | 12 |
| Month 138 — Improvement | 10 |
| Month 138 — Stable | 39 |
| Month 138 — Deterioration | 18 |
| Month 141 — Improvement | 6 |
| Month 141 — Stable | 18 |
| Month 141 — Deterioration | 12 |
| Month 144 — Improvement | 7 |
| Month 144 — Stable | 30 |
| Month 144 — Deterioration | 19 |
| Month 147 — Improvement | 6 |
| Month 147 — Stable | 21 |
| Month 147 — Deterioration | 15 |
| Month 150 — Improvement | 7 |
| Month 150 — Stable | 22 |
| Month 150 — Deterioration | 15 |
| Month 153 — Improvement | 8 |
| Month 153 — Stable | 16 |
| Month 153 — Deterioration | 8 |
| Month 156 — Improvement | 3 |
| Month 156 — Stable | 9 |
| Month 156 — Deterioration | 5 |
| Month 159 — Improvement | 1 |
| Month 159 — Stable | 2 |
| Month 159 — Deterioration | 6 |
| Month 162 — Improvement | 0 |
| Month 162 — Stable | 1 |
| Month 162 — Deterioration | 1 |
| End of study — Improvement | 610 |
| End of study — Stable | 2419 |
| End of study — Deterioration | 785 |
| Month 3 follow-up — Improvement | 203 |
| Month 3 follow-up — Stable | 907 |
| Month 3 follow-up — Deterioration | 381 |
| Month 6 follow-up — Improvement | 29 |
| Month 6 follow-up — Stable | 111 |
| Month 6 follow-up — Deterioration | 88 |
The EDSS is a scale for assessing neurological impairment in MS (Kurtzke 1983) including (1) a series of scores in each of eight functional systems, and (2) the EDSS steps (ranging from 0 (normal) to 10 (death due to MS). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Based on the assessment of each FS, the participant's overall score is determined between 0 to 10. A negative change from baseline indicates improvement. Only descriptive analysis performed.
| EDDS Overall Score | Fingolimod 0.5 mg/Day |
|---|---|
| Baseline (BL) | 2.39 ± 1.452 |
| Change from BL at Month 3 | -0.06 ± 0.638 |
| Change from BL at Month 6 | -0.07 ± 0.716 |
| Change from BL at Month 9 | -0.09 ± 0.750 |
| Change from BL at Month 12 | -0.07 ± 0.815 |
| Change from BL at Month 15 | -0.08 ± 0.814 |
| Change from BL at Month 18 | -0.05 ± 0.890 |
| Change from BL at Month 21 | -0.08 ± 0.876 |
| Change from BL at Month 24 | -0.01 ± 0.916 |
| Change from BL at Month 27 | -0.03 ± 0.932 |
| Change from BL at Month 30 | -0.00 ± 0.935 |
| Change from BL at Month 33 | -0.02 ± 0.951 |
| Change from BL at Month 36 | 0.01 ± 0.997 |
| Change from BL at Month 39 | 0.02 ± 0.963 |
| Change from BL at Month 42 | 0.04 ± 1.015 |
| Change from BL at Month 45 | 0.06 ± 1.006 |
| Change from BL at Month 48 | 0.06 ± 1.063 |
| Change from BL at Month 51 | 0.06 ± 1.071 |
| Change from BL at Month 54 | 0.04 ± 1.120 |
| Change from BL at Month 57 | 0.09 ± 1.077 |
| Change from BL at Month 60 | 0.17 ± 1.144 |
| Change from BL at Month 63 | 0.08 ± 1.123 |
| Change from BL at Month 66 | 0.15 ± 1.220 |
| Change from BL at Month 69 | 0.14 ± 1.116 |
| Change from BL at Month 72 | 0.22 ± 1.205 |
| Change from BL at Month 75 | 0.13 ± 1.159 |
| Change from BL at Month 78 | 0.28 ± 1.259 |
| Change from BL at Month 81 | 0.18 ± 1.158 |
| Change from BL at Month 84 | 0.25 ± 1.236 |
| Change from BL at Month 87 | 0.24 ± 1.206 |
| Change from BL at Month 90 | 0.29 ± 1.282 |
| Change from BL at Month 93 | 0.18 ± 1.219 |
| Change from BL at Month 96 | 0.31 ± 1.355 |
| Change from BL at Month 99 | 0.18 ± 1.220 |
| Change from BL at Month 102 | 0.30 ± 1.332 |
| Change from BL at Month 105 | 0.21 ± 1.320 |
| Change from BL at Month 108 | 0.28 ± 1.270 |
| Change from BL at Month 111 | 0.24 ± 1.343 |
| Change from BL at Month 114 | 0.30 ± 1.258 |
| Change from BL at Month 117 | 0.35 ± 1.389 |
| Change from BL at Month 120 | 0.40 ± 1.271 |
| Change from BL at Month 123 | 0.60 ± 1.302 |
| Change from BL at Month 126 | 0.38 ± 1.441 |
| Change from BL at Month 129 | 0.40 ± 1.448 |
| Change from BL at Month 132 | 0.40 ± 1.450 |
| Change from BL at Month 135 | 0.51 ± 1.519 |
| Change from BL at Month 138 | 0.42 ± 1.527 |
| Change from BL at Month 141 | 0.54 ± 1.509 |
| Change from BL at Month 144 | 0.60 ± 1.553 |
| Change from BL at Month 147 | 0.67 ± 1.640 |
| Change from BL at Month 150 | 0.44 ± 1.483 |
| Change from BL at Month 153 | 0.23 ± 1.534 |
| Change from BL at Month 156 | 0.26 ± 1.427 |
| Change from BL at Month 159 | 1.17 ± 1.369 |
| Change from BL at Month 162 | 0.75 ± 1.061 |
| Change from BL at End of study | 0.14 ± 1.108 |
| Change from BL at Month 3 follow-up | 0.29 ± 1.248 |
| Change from BL at Month 6 follow-up | 0.56 ± 1.487 |
Collected over Adverse events were collected from first dose of study treatment in Study Part I until end of study treatment in Study Part II plus 6 weeks post treatment, up to a maximum duration of 8 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod 0.5 mg/Day | 16/4,083 (0.4%) | 515/4,083 (12.6%) | 2,125/4,083 (52%) |
| Event | Fingolimod 0.5 mg/Day |
|---|---|
| Multiple sclerosis relapseNervous system disorders | 34/4083 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 30/4083 |
| PneumoniaInfections and infestations | 14/4083 |
| Urinary tract infectionInfections and infestations | 14/4083 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 11/4083 |
| CholelithiasisHepatobiliary disorders | 10/4083 |
| AppendicitisInfections and infestations | 10/4083 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/4083 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 10/4083 |
| Herpes zosterInfections and infestations | 9/4083 |
| Event | Fingolimod 0.5 mg/Day |
|---|---|
| NasopharyngitisInfections and infestations | 706/4083 |
| HeadacheNervous system disorders | 348/4083 |
| Upper respiratory tract infectionInfections and infestations | 346/4083 |
| Urinary tract infectionInfections and infestations | 335/4083 |
| Back painMusculoskeletal and connective tissue disorders | 279/4083 |
| InfluenzaInfections and infestations | 275/4083 |
| HypertensionVascular disorders | 243/4083 |
| FatigueGeneral disorders | 232/4083 |
| LymphopeniaBlood and lymphatic system disorders | 219/4083 |
| BronchitisInfections and infestations | 214/4083 |
Participant Flow and Baseline Characteristics were based on the Enrolled set. Efficacy analyses were based on the Fingolimod Full Analysis Set..
| Age, Continuous(years) | Fingolimod 0.5 mg/Day |
|---|---|
| Mean | 37.8 ± 9.05 |
| Age, Customized(Participants) | Fingolimod 0.5 mg/Day |
|---|---|
| < 18 years | 1 |
| 18 - 30 years | 951 |
| 31 - 40 years | 1497 |
| 41 - 55 years | 1605 |
| > 55 years | 71 |
| Sex: Female, Male(Participants) | Fingolimod 0.5 mg/Day |
|---|---|
| Female | 2933 |
| Male | 1192 |
| Race/Ethnicity, Customized(Participants) | Fingolimod 0.5 mg/Day |
|---|---|
| Caucasian | 3927 |
| Black | 38 |
| Asian | 35 |
| Native American | 11 |
| Other | 114 |
Showing the first 100 of 458 sites across 38 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Sep 2010 to primary completion in Oct 2018, 97 months.
Results were first posted in Nov 2019, 1 year after primary completion.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 97 months is above that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod